Altris AI launches advanced glaucoma Optic Disc Analysis module

News
Article

Key parameters captured by the module include disc area, cup area, cup volume, minimal cup depth, maximum cup depth, cup/disc area ratio, rim absence angle, and disc-damage likelihood scale.

AI graphic of motherboard Image credit: AdobeStock/Kaikoro

Image credit: AdobeStock/Kaikoro

Altris AI has announced the launch of an advanced glaucoma Optic Disc Analysis module intended to aid in the early detection of the disease. The new artificial intelligence (AI) module builds upon an earlier innovation that utilizes Ganglion Cell Complex (GCC) Asymmetry Analysis that will enhance improvements from the Altris AI macula module, according to a news release.

“The launch of our Advanced Optic Disc Analysis module marks a pivotal step forward in glaucoma care,” said Maria Znamenska, MD, PhD, chief medical officer at Altris AI, in the release. “By combining the gold standard of optic disc evaluation with AI-powered precision, we’re equipping eye care professionals with the tools to make more accurate and timely diagnosis of this vision-threatening disorder. This innovation not only reduces false positive referrals but also enhances early detection and treatment planning—ensuring better outcomes for patients and optimizing healthcare resources. Together with GCC asymmetry analysis, our platform empowers clinicians to elevate the standard of glaucoma care, offering hope to millions at risk of vision loss.”

Key parameters captured by the module include disc area, cup area, cup volume, minimal cup depth, maximum cup depth, cup/disc area ratio, rim absence angle, and disc-damage likelihood scale. Optic disc parameters are evaluated by the module using optical coherence tomography (OCT), which allows for personalized assessments by accounting for individual disc sizes and angle of rim absence. Additionally, the platform assigns a severity score for optic disc damage on a scale of 1 to 10.

The Altris Glaucoma Module is compatible with 3D OCT optic disc, horizontal wide, and vertical-wide scans, as well as OCT optic disc raster scans. Cross-evaluation is available across these OCT systems, which allows eye care providers to analyze both macula and optic disc pathology, even if data originates from multiple OCT devices.

Altris launched its AI-powered Advanced Optic Disc Analysis module in February 2025.

Reference
  1. Altris AI launches advanced Optic Disc Analysis for glaucoma. News release. Altris AI. Accessed March 3, 2025. https://www.altris.ai/article/altris-ai-launches-advanced-optic-disc-analysis-for-glaucoma-complementing-gcc-asymmetry-analysis/

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Drs Brianna Rhue and Diana Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
© 2025 MJH Life Sciences

All rights reserved.